Cargando…

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190388/ https://www.ncbi.nlm.nih.gov/pubmed/32425515 http://dx.doi.org/10.2147/COPD.S259017

Ejemplares similares

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis
por: Barjaktarevic, Igor Z, et al.
Publicado: (2019)

Differences in clinical significance of bronchodilator responses measured by forced expiratory volume in 1 second and forced vital capacity
por: Choi, Joon Young, et al.
Publicado: (2023)

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]
Publicado: (2018)

Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort
por: Han, MeiLan K., et al.
Publicado: (2017)

Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort
por: Opron, Kristopher, et al.
Publicado: (2021)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts
por: Fawzy, Ashraf, et al.
Publicado: (2018)

Promoting the inclusion of vital-capacity data in the bronchodilator response
por: Ben Saad, Helmi
Publicado: (2017)

Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort
por: Hastie, AT, et al.
Publicado: (2017)

Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort
por: Zhang, William Z., et al.
Publicado: (2021)

Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort
por: Cooper, Christopher B, et al.
Publicado: (2020)

Role of the Bronchodilator Test Defined by the Forced Vital Capacity in Chronic Obstructive Pulmonary Disease Phenotyping
por: Zhang, Xiaoling, et al.
Publicado: (2020)

Image-Enhanced Bronchoscopic Evaluation of Bronchial Mucosal Microvasculature in COPD [Corrigendum]
Publicado: (2022)

Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease [Corrigendum]
Publicado: (2022)

Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
por: Putcha, Nirupama, et al.
Publicado: (2018)

Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study
por: Hansel, Nadia N, et al.
Publicado: (2017)

The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS
por: Wells, J. Michael, et al.
Publicado: (2019)

Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study
por: Azevedo, Karen S, et al.
Publicado: (2012)

COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]
Publicado: (2014)

Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS
por: Fernández-Baldera, Antonio, et al.
Publicado: (2017)

Corrigendum to “Recommendations for Diagnosis and Management of Osteoporosis in COPD Men”
por: Mazokopakis, Elias E., et al.
Publicado: (2017)

Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS
por: Zhang, William Z., et al.
Publicado: (2020)

Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS)
por: Haghighi, Babak, et al.
Publicado: (2019)

Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
por: Haghighi, Babak, et al.
Publicado: (2018)

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]
Publicado: (2019)

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]
Publicado: (2019)

Nasal high-flow in acute hypercapnic exacerbation of COPD [Corrigendum]
Publicado: (2019)

Repetitive Saliva Swallowing Test Predicts COPD Exacerbation [Corrigendum]
Publicado: (2021)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Corrigendum to “Expression of HE4 in Endometrial Cancer and Its Clinical Significance”
por: Li, Xiao, et al.
Publicado: (2018)

Progression Of Physical Inactivity In COPD Patients: The Effect Of Time And Climate Conditions – A Multicenter Prospective Cohort Study [Corrigendum]
Publicado: (2019)

Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
por: Zou, Chunrui, et al.
Publicado: (2021)

Molecular Epidemiology And Clinical Significance Of Corynebacterium Striatum Isolated From Clinical Specimens [Corrigendum]
Publicado: (2019)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Predicting frequent COPD exacerbations using primary care data [Corrigendum]
Publicado: (2018)

The Relationship Between Morning Symptoms and the Risk of Future Exacerbations in COPD [Corrigendum]
Publicado: (2021)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Corrigendum to: Aortic flow is associated with aging and exercise capacity
Publicado: (2023)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ddg6h38t594js4dub5m0feqcpa